LILLE, France--(BUSINESS WIRE)-- #PSP--Alzprotect today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for AZP2006 (Ezeprogind®) for the treatment of Progressive Supranuclear Palsy (PSP). FDA clearance permits the Company to begin clinical development of AZP2006 in the United States. "FDA IND clearance is a pivotal step in our PSP program,a€™ said Philippe Verwaerde, PhD, President & Chief science Officer. "We can now e. ...